Font

Aa Aa Aa

Background color

A A

Site version

Color Black and white
Drugs

Vasoclean-Darnitsa

Drugs lowering triglyceride and cholesterol levels in blood serum. HMG-CoA-reductase inhibitors

Atorvastatin is a synthetic hypolipidemic drug. Atorvastatin is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase.

Prevention of cardiovascular diseases

In patients without clinical manifestations of ischemic heart disease but with several risk factors for its development, such as age, smoking, arterial hypertension, low HDL, or early ischemic heart disease in the family history, atorvastatin is indicated:

– To decrease the risk of myocardial infarction

– To decrease the risk of stroke

– To decrease the risk of revascularization procedures and angina

Hyperlipidemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson types IIa and IIb)

The recommended initial dose of atorvastatin is 10 or 20 mg once daily. For patients needing a significant LDL decrease (by more than by 45%), the treatment can be started from 40 mg once daily. The dose range of the drug is from 10 to 80 mg once daily. The drug should be taken once at any time of day, regardless of food intake. The initial and maintenance doses of atorvastatin should be selected individually depending on treatment goal and patient response. After the start of the treatment and/or dose titration, the lipid level should be analyzed over 2–4 weeks. With the dose appropriately adjusted.

Specialized edition for medical institutions and doctors.